Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,735,437 | 1,779,301 | -78,710 | -241,361 | -147,757 |
| Depreciation Amortization | 1,596 | 836 | 1,602 | 6,090 | 4,545 |
| Accounts receivable | -100 | -100 | 0 | -535 | -88 |
| Accounts payable and accrued liabilities | 21,022 | 21,472 | 4,050 | 2,109 | -801 |
| Other Working Capital | 52,047 | 42,687 | 7,196 | 15,348 | -13,007 |
| Other Operating Activity | -1,960,691 | -1,964,604 | 2,812 | 25,040 | 20,620 |
| Operating Cash Flow | $-150,689 | $-120,408 | $-63,050 | $-193,309 | $-136,488 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,581 | -2,334 | -1,119 | -4,593 | -1,151 |
| Investing Cash Flow | $-2,581 | $-2,334 | $-1,119 | $-4,593 | $-1,151 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 71,678 | 71,678 | 38,728 | 202,316 | 201,231 |
| Other Financing Activity | 0 | 0 | 0 | -355 | -130 |
| Financing Cash Flow | $71,678 | $71,678 | $38,728 | $201,961 | $201,101 |
| Beginning Cash Position | 277,924 | 277,924 | 277,924 | 273,865 | 273,865 |
| End Cash Position | 196,332 | 226,860 | 252,483 | 277,924 | 337,327 |
| Net Cash Flow | $-81,592 | $-51,064 | $-25,441 | $4,059 | $63,462 |
| Free Cash Flow | |||||
| Operating Cash Flow | -150,689 | -120,408 | -63,050 | -193,309 | -136,488 |
| Capital Expenditure | -2,581 | -2,334 | -1,119 | -4,593 | -1,151 |
| Free Cash Flow | -153,270 | -122,742 | -64,169 | -197,902 | -137,639 |